top of page
Science Data Updates

Raphael Pharmaceutical Announces Positive Proof-of-Concept Clinical Study Results for the Company’s Cannabinoid based Formula, for the Treatment of Rheumatoid Arthritis

New York, NY – January 7, 2025 – Raphael Pharmaceutical Inc. (“Raphael Pharmaceutical” or the “Company”) (OTCQB: RAPH), a clinical-stage biotechnology company advancing a novel cannabinoid-based research platform, today announced positive proof-of-concept clinical study results for the Company’s formula, for the management of rheumatoid arthritis (“RA”).  Citruslabs, a leading contract research organization, successfully completed this proof-of-concept clinical study in the United States under Institutional Review Board (“IRB”) approval and in compliance with U.S. Food and Drug Administration (“FDA”)
By Week 4, Raphael’s formula significantly improved:
● Pain levels.
● The ability to live life to the fullest.
● The ability to pursue passions and hobbies.
● The ability to enjoy relationships.
● The ability to enjoy daily life.
● Sleep rating.
● Relaxation rating.
● DAS28 score.


Raphael’s formula improved DAS28 scores from high disease activity to moderate disease severity by Week 4,

Publications

       2020 Raphael Pharmaceutical Ltd. All rights reserved    |    Andrei Saharov 9, Haifa, Israel      |

Shlomipilo1@gmail.com    |   +972-52-77-55-072

bottom of page